3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Follicular
6
Prostatic Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Urinary Bladder Neoplasms
1
Sarcoma, Synovial
1
Sarcoma
1
Rhabdoid Tumor
1
Multiple Myeloma
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Lymphoma
1
Hematologic Neoplasms
1
Chordoma
1
Carcinoma, Transitional Cell
1
Interventions
pembrolizumab
9
Pemetrexed
7
Cyclophosphamide
6
Nivolumab
5
Ipilimumab
5
Cisplatin
5
Carboplatin
5
fludarabine
4
Drug Therapy
2
Bevacizumab
2
tremelimumab
1
tocilizumab
1
tazemetostat
1
spartalizumab
1
sotorasib
1
rebastinib
1
poly ICLC
1
pevonedistat
1
osimertinib
1
milademetan
1
fludarabine phosphate
1
epacadostat
1
durvalumab
1
defactinib
1
atezolizumab
1
aldesleukin
1
Vorinostat
1
Thiostrepton
1
Tablets
1
Plicamycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Mesothelioma
×
tazemetostat
×
Clear all
NCT02875548
2025-11-04
TRuST
Ipsen
Phase 1/2
Completed
58 enrolled